Ally Olotu

In the News

Swiss envoys visit Bagamoyo sites to boost ties

(Bagamoyo) Swiss Ambassador to Tanzania Florence Tinguely Mattli and Head of Sub-Saharan Africa and Francophone Division in the Swiss Department of Foreign Affairs Ambassador Anne Lugon-Moulin visited Ifakara Health Institute’s …

IHI, partners kick off China-TZ malaria project

(Dar es Salaam) Ifakara Health Institute (IHI) today joins public health partners in hosting the kick off meeting for the China-Tanzania malaria project to be implemented for one year from …

Recent Projects

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Ally Olotu

Research Scientist & Clinician

Dr Ally Olotu is research physician with expertise in malaria epidemiology and clinical trials addressing malaria interventions such as malaria vaccines. After 2 years of clinical practice at Aga Khan Hospital in Dar es salaam, Tanzania he worked as a research clinician within several clinical studies of malaria pathogenesis at KEMRI-Wellcome Trust, Kenya. In 2005, he was awarded a WHO/TDR Career Development Fellowship in malaria vaccine development and spent a year at GSK Biologicals in Rixensart, Belgium and WHO/TDR headquarters in Geneva, Switzerland where he received training in training in malaria vaccine research and development and clinical trials management. He was also involved in coordinating two malaria vaccine trials in West Africa and played a role in the development of clinical trial protocols and standard operating procedures. He was a Co-PI in a multi-centre trial evaluating the safety and efficacy of RTS,S/AS01, a candidate malaria vaccine, and participated in setting up a clinical trial facility which provided support to the trial.  After the end of the industry-sponsored study, and under the supervision of Dr Philip Bejon, He initiated an investigator-led extension which formed the basis of his DPhil work which started in 2010 and ended in 2014. In 2015, He joined the Ifakara Health Institute where he was assigned to supervise the Equatorial Guinea Malaria Vaccine Initiative research project in Malabo, Bioko Island. Over the last 2 years, and working with both the public and private partners, he participated in the development of the protocols and SOPs for a whole sporozoite vaccine trial and trained a clinical trial team which successfully implemented the first ever clinical trial in the history of Equatorial Guinea.  His main contribution has been on the investigation of the long-term efficacy of a candidate malaria vaccine (RTS,S/AS01) in young children living in a malaria endemic country. He has also described the interaction between the vaccine efficacy and malaria exposure. In addition he has studied immunological markers of vaccine efficacy and of naturally-acquired infection. His research to-date has led to several publication in peer reviewed journals. In 2013 he won the Oxford University Nuffield Department of Medicine Graduate Research Prize for his DPhil work. He is currently collaborating with Sanaria Inc, Medical Care Development International in Equatorial Guinea and Swiss Tropical Public Health Institute

View Dr. Olotu’s Research Interests and Publications

Projects

Evaluation of whole sporozoite vaccines for malaria elimination

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016